Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Harnessing Memory NK Cell to Protect Against COVID-19
Saeede Soleimanian, Ramin Yaghobi
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application
Wei Zuo, Xiaosu Zhao
Clinical Immunology (2021) Vol. 227, pp. 108727-108727
Open Access | Times Cited: 60
Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
Clara Di Vito, Francesca Calcaterra, Nicolò Coianiz, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 59
Natural Killer cells in COVID-19: from Infection, to Vaccination and Therapy
Alireza Zafarani, Mohammad Hossein Razizadeh, Salar Pashangzadeh, et al.
Future Virology (2023) Vol. 18, Iss. 3, pp. 177-191
Open Access | Times Cited: 27
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection
Roberto Littera, Luchino Chessa, Silvia Deidda, et al.
PLoS ONE (2021) Vol. 16, Iss. 8, pp. e0255608-e0255608
Open Access | Times Cited: 47
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Angélica Cuapio, Caroline Boulouis, Iva Filipovic, et al.
Molecular Medicine (2022) Vol. 28, Iss. 1
Open Access | Times Cited: 34
HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity
Anahit Hovhannisyan, Vergine Madelian, Sevak Avagyan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Natural killer cells and their exosomes in viral infections and related therapeutic approaches: where are we?
Mohammad Hossein Razizadeh, Alireza Zafarani, Mahsa Taghavi-Farahabadi, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 13
NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19
Laura Bergantini, Miriana d’Alessandro, Paolo Cameli, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3182-3182
Open Access | Times Cited: 28
The causal effect of natural killer cells on COVID-19 infection, hospitalization and severity
Kaili Yang, Jun Quan, Zhi Long Liu, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Closed Access
Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects
Yizhao Chen, Chong Liu, Yilong Fang, et al.
Biochemical Pharmacology (2024) Vol. 222, pp. 116066-116066
Closed Access | Times Cited: 3
Branched‐Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice
Daria M. Strelkova Petersen, Ryan M. Weiss, Khalid A. Hajj, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 22
Closed Access | Times Cited: 3
Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells
Babak Arjmand, Sepideh Alavi-Moghadam, Masoumeh Sarvari, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 1, pp. 171-206
Open Access | Times Cited: 9
Expansion of CD56dimCD16neg NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients
José L. Casado, Elisa Moraga, Pilar Vizcarra, et al.
Viruses (2021) Vol. 14, Iss. 1, pp. 46-46
Open Access | Times Cited: 19
A comparative study of serum Zn, Cu, Mg, Mn, Cr, and Fe levels and their association with the vulnerability of Iraqi COVID-19 patients
Falah S. Al-Fartusie, Safaa I. Kader, Sara Jassim Mohammed, et al.
Journal of Trace Elements in Medicine and Biology (2023) Vol. 79, pp. 127242-127242
Open Access | Times Cited: 7
Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19
Mohammad Ahmadvand, Mahdieh Shokrollahi Barough, Zahra Sadat Hashemi, et al.
Pilot and Feasibility Studies (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Evaluation of favipiravir in the treatment of COVID-19 based on the real-world
Weishang Deng, Changyuan Yang, Sensen Yang, et al.
Expert Review of Anti-infective Therapy (2021) Vol. 20, Iss. 4, pp. 555-565
Open Access | Times Cited: 17
Possibility of intrauterine transmission from mother to fetus/newborn: Systematic review and meta-analysis of diagnostic methods to detect SARS-CoV-2 infection
Pouria Khodavandi, Alireza Khodavandi, Fahimeh Alizadeh, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology (2024) Vol. 295, pp. 181-200
Closed Access | Times Cited: 2
Unlocking therapeutic potential: integration of drug repurposing and immunotherapy for various disease targeting.
Vishakha Anand Pawar, Anuradha Tyagi, Chaitenya Verma, et al.
PubMed (2023) Vol. 15, Iss. 8, pp. 4984-5006
Closed Access | Times Cited: 6
Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges
Bernice Oh, Louis Wei Yong Chan, Louis Yi Ann Chai
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 4
Comparison of Serum Zn, Cu, Mg, Mn, Cr, and Fe Levels in Iraqi COVID-19 Patients and their Association with Infection Severity
Falah S. Al-Fartusie, Safaa Kader, Sara Jassim Mohammed, et al.
Indian Journal of Clinical Biochemistry (2024)
Closed Access | Times Cited: 1
Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?
Manuel Guerreiro, C. Aguilar, Juan Montoro, et al.
Transplant Infectious Disease (2021) Vol. 23, Iss. 4
Open Access | Times Cited: 9
Characteristics of T-cell immunity and level of the natural killer cells content in COVID-19 convalescents with carbohydrate metabolism disorders
K. S. Savchuk
Medical Immunology (Russia) (2023) Vol. 25, Iss. 4, pp. 797-802
Open Access | Times Cited: 3
New Approach for Targeted Treatment of Mild COVID-19 by Honeysuckle through Network Pharmacology Analysis
Huijuan Li, Yan Li, Chunxiang Luo, et al.
Computational and Mathematical Methods in Medicine (2022) Vol. 2022, pp. 1-12
Open Access | Times Cited: 5
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
Xuesong He, Xiao Xue Zeng
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 951-972
Open Access | Times Cited: 5
Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019
Koushik Chakrabarty, Rohit Shetty, Shubham Argulwar, et al.
Cytotherapy (2021) Vol. 24, Iss. 3, pp. 235-248
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top